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Editorial on the Research Topic
Oxidative Stress: How Has It Been Considered in the Design of New Drug Candidates for
Neurodegenerative Diseases?
Central Nervous System (CNS) disorders affect millions of people worldwide (Feigin et al., 2019).
Despite their growing impact on health systems and the urgent need for new, safer, and more
effective drugs, the Pharmaceutical Industries have avoided efforts to develop new candidates due to
high costs and low success rates in the clinical phase (Seyhan, 2019), mainly because of the
insufficient knowledge of the mechanisms underlying CNS dysfunctions (Gribkoff and Kaczmarek,
2017).
In this scenario, neurodegenerative diseases (NDs), i.e., those that result from loss of function and
death of nerve cells in the brain or peripheral nervous system, such as Parkinson’s disease (PD),
Alzheimer’s disease (AD), Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS),
deserve to be highlighted due to their increasing prevalence, most of the time dependent on age, and
the absence of treatments capable of controlling and reversing the processes associated with their
pathogenesis (Martin, 1999). Therefore, the need for a better understanding of the complex
mechanisms associated with the genesis of NDs and the development of new therapeutically
effective approaches become essential (Golde, 2009; Santiago et al., 2017).
Although the clinical and neuropathological aspects of these disorders are distinct and most have
the formation of abnormal protein deposits as a crucial factor associated with their onset, all have a
common and characteristic pattern of neuronal degeneration in anatomically or functionally related
regions (Vadakkan, 2016). Moreover, oxidative stress (OS) is considered as a common key player in
the etiology and progression of these NDs and, for this reason, it could be observed a significant
increase of interest in searching antioxidant and also anti-inflammatory effects of diverse classes of
natural and synthetic compounds as promising drug candidates for the treatment of NDs (Chen
et al., 2012).
Abundant literature data suggest that OS may induce not only cellular and membrane damage,
but also DNA repair system breakdown or mitochondrial disfunction, contributing to a complex
network of events related to energy supply, neurodegeneration and aging, a phenomena observed in
AD or PD, for example (Schieber and Chandel, 2014). Increased reactive oxygen species (ROS) levels
is a prompt consequence of OS and it is usually related to down-regulation in several defense systems
including antioxidant enzymes or endogenous small-molecule antioxidants (Sayre et al., 2001). In
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this context, several hypotheses have been recently proposed to
explain the complexity and multifactorial pathogenesis of AD,
including OS as not only a central player, but, perhaps, one of the
main causative factors of NDs, unifying a series of other
sequential or individual pathophysiological events (Singh et al.,
2019). According to this consensus, oxidative damage in the brain
of patients is resultant from excessive production of free radicals
induced by fragments of insoluble and/or overproduced proteins,
such as β-amyloid peptide, α-synuclein, tau and huntingtin, with
functional alteration in the mitochondria, inadequate energy
supply, production of inflammatory mediators and alteration
of antioxidant defenses (Islam, 2016; Liu et al., 2017). Thus,
the modulation of the cellular oxidative process should lead to a
new concept in the design of drugs and, possibly, a new way of
searching for more effective disease-modifying chemical entities,
reinforcing the hope of at least real clinical relief, if healing is not
yet possible (Ghosh et al., 2011; Rekatsina et al., 2020).
The collection of research articles and reviews that composed
this Research Topic clearly demonstrate some advances to better
understand the role of OS in the mechanisms associated with the
genesis of NDs and the ability of some natural products to
modulate these phenomena. In this context, the paper by
Huang et al. (2020) describes the neuroprotective effects of
α-cyperone, a terpene isolated from Cyperus rotundus, against
hydrogen peroxide (H2O2)-induced OS and apoptosis in
dopaminergic neuronal SH-SY5Y cells, used as models to
study PD. Their findings indicated that α-cyperone, which is
well-known to inhibit neuroinflammation, was able to decrease
H2O2-induced death and production of ROS in SH-SY5Y cells,
through a mechanism dependent on the activation of nuclear
factor erythroid 2-related factor 2 (Nrf-2), which is a key
transcription factor for the regulation of antioxidant proteins
expression. This behavior makes this class of natural products
attractive in the search for newer therapies for treatment of PD.
Mhillaj et al. (2019) described in their review the effects of the
natural antioxidant products ferulic acid, resveratrol and Ginkgo
biloba extracts on heme oxygenase/biliverdin reductase system,
which could be responsible for producing OS in neurons under
unbalanced redox conditions. Despite countless preclinical studies
with these herbal products demonstrating their neuroprotective
effects, the compiled results were not sufficiently indicative of the
efficacy of these natural products for NDs treatment, mainly
because most of them showed poor bioavailability in humans.
On the contrary, the results highlight the importance of taking care
with the use of these herbal-derived products due to their ability to
promote drug interactions resulting from their inhibitory or up-
regulatory actions on different CYP isoforms.
On the other hand, the paper of Zhou et al. (2019) described
the anti-inflammatory effects of cryptotanshinone, a diterpene
extracted from Salvia miltiorrhiza, in neuroinflammation models
induced by lipopolysaccharide in BV-2 microglial cells. By
modulating Nrf2/heme-oxygenase 1 signaling pathway
cryptotanshinone attenuates the upregulated expression of
several proinflammatory proteins, such as inducible nitric
oxide synthase, cyclooxygenase 2, NOD-like receptor pyrin
domain-containing-3 (NLRP3), and it also reduces the
increased release of pro-inflammatory cytokines, such as
interleukin-1β, interleukin-6 and tumor necrosis factor-α.
These results were important to elucidate the mechanisms
associated with the anti-inflammatory effects of
cryptotanshinone, opening new horizons for the possibility of
research and development of new analogues for the therapy of
NDs related with microglial cell activation.
Moreover, the actions promoted by the commonly found natural
product luteolin on Nrf-2 translocation to the nucleus and the
improvement of the expression of antioxidant proteins were the
subject of the paper by Tan et al. (2020). Their findings indicated the
beneficial neuroprotective effects of this flavonoid in intracerebral
hemorrhage induced secondary brain injury, through the
enhancement of autophagy and anti-oxidative processes
dependent on activation of the p62-Keap1-Nrf2 pathway.
Some endogenous thiols, such as the redox couples
glutathione/glutathione disulfide, cysteine/cystine and
thioredoxin-reduced/thioredoxin-oxidized, are well known as
markers of OS because of their antioxidant and cellular
protective roles. Therefore, the paper by Paul and Snyder
reviewed the role of the cysteamine, an aminothiol resultant
from decarboxylation of amino acid cysteine, and its oxidized
disulfide form cystamine in the progression of NDs through the
modulation of different multiple targets, such as those from
brain-derived neurotrophic factors and Nrf2 signaling
pathways. The authors reported many evidences of the
participation of cysteamine/cystamine and/or their metabolites
in the reduction of OS and, consequently, promoting
upregulation of cytoprotective effects in HD and other NDs.
The search for new small molecule bioactive compounds able
to modulate receptors stimulated by lipid mediator sphingosine-
1-phosphate (S1P) represents a great opportunity to discover
drug candidates for NDs. One example is the agonist S1P receptor
fingolimod, approved by FDA in 2010 as the first oral treatment
for multiple sclerosis, but that also demonstrated ability to
promote neuroprotection in animal models of PD. Stimulated
by these previous results, Pépin et al. (2020) investigated the
profile of compound SEW2871, a selective agonist of S1P
receptors in animal models of PD. The obtained results clearly
indicated that SEW2871 presented a neuroprotective activity
similar to that displayed by fingolimod in 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine-induced mouse model of PD, being a
promising candidate for treatment of this ND.
Last, but not least, the paper by Cassano et al. (2020) reviewed
the therapeutic effects of cannabidiol, a non-psychoactive
component of Cannabis sativa, highlighting not only its profile
as a cannabinoid receptors antagonist, but also as a modulator of
multiple signaling pathways and receptors, such as the N-methyl-
D-aspartate. Thus, its ability to stimulate the production of
important anti-inflammatory and antioxidant endogenous
molecules makes this natural product an important drug
candidate for treatment of different NDs.
For our concluding remarks, the contributions of this
Research Topic indicated that, despite the morphological and
biochemical differences among NDs, OS is recognized as a
common component of these pathological conditions. In
addition, many natural products belonging to different
chemical classes and synthetic derivatives have been shown to
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be able to modulate OS by controlling ROS levels directly or
indirectly by increasing the expression of antioxidant proteins,
being important therapeutic alternatives for the treatment of
NDs, possibly in combination with other therapies.
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